- Home
- INSW vs ARVN Comparison
INSW vs ARVN Comparison
Compare INSW & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- ARVN
- Stock Information
- Founded
- INSW 1999
- ARVN 2015
- Country
- INSW United States
- ARVN United States
- Employees
- INSW N/A
- ARVN N/A
- Industry
- INSW Semiconductors
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- INSW Technology
- ARVN Health Care
- Exchange
- INSW Nasdaq
- ARVN Nasdaq
- Market Cap
- INSW 2.1B
- ARVN 1.8B
- IPO Year
- INSW N/A
- ARVN 2018
- Fundamental
- Price
- INSW $34.16
- ARVN $18.97
- Analyst Decision
- INSW Strong Buy
- ARVN Strong Buy
- Analyst Count
- INSW 3
- ARVN 13
- Target Price
- INSW $60.67
- ARVN $63.00
- AVG Volume (30 Days)
- INSW 666.5K
- ARVN 855.2K
- Earning Date
- INSW 11-07-2024
- ARVN 10-30-2024
- Dividend Yield
- INSW 17.35%
- ARVN N/A
- EPS Growth
- INSW N/A
- ARVN N/A
- EPS
- INSW 10.33
- ARVN N/A
- Revenue
- INSW $1,007,734,000.00
- ARVN $161,100,000.00
- Revenue This Year
- INSW N/A
- ARVN $237.44
- Revenue Next Year
- INSW $1.61
- ARVN N/A
- P/E Ratio
- INSW $3.22
- ARVN N/A
- Revenue Growth
- INSW N/A
- ARVN 1.07
- 52 Week Low
- INSW $32.75
- ARVN $18.51
- 52 Week High
- INSW $65.94
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- INSW 22.99
- ARVN 31.95
- Support Level
- INSW $32.73
- ARVN $18.51
- Resistance Level
- INSW $38.23
- ARVN $19.90
- Average True Range (ATR)
- INSW 1.04
- ARVN 1.55
- MACD
- INSW -0.24
- ARVN -0.64
- Stochastic Oscillator
- INSW 14.88
- ARVN 5.65
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.